Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Visual acuity loss" patented technology

Loss of visual acuity in one eye: Loss of visual acuity in one eye refers to the loss of sharp, clear vision in one eye. See detailed information below for a list of 14 causes of Loss of visual acuity in one eye, Symptom Checker, including diseases and drug side effect causes.

Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids

Nucleic acid vectors encoding light-gated cation-selective membrane channels, in particular channelrhodopsin-2 (Chop2), converted inner retinal neurons to photosensitive cells in photoreceptor-degenerated retina in an animal model. Such treatment restored visual perception and various aspects of vision. A method of restoring light sensitivity to a retina of a subject suffering from vision loss due to photoreceptor degeneration, as in retinitis pigmentosa or macular degeneration, is provided. The method comprises delivering to the subject by intravitreal or subretinal injection, the above nucleic acid vector which comprises an open reading frame encoding a rhodopsin, to which is operatively linked a promoter and transcriptional regulatory sequences, so that the nucleic acid is expressed in inner retinal neurons. These cells, normally light-insensitive, are converted to a light-sensitive state and transmit visual information to the brain, compensating for the loss, and leading to restoration of various visual capabilities.
Owner:WAYNE STATE UNIV +1

Nutritional supplement for treatment of ocular diseases

A nutritional supplement composition that promotes visual health and reduces or reverses visual acuity loss by a reduced Vitamin E content from standard supplements with the addition of taurine, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and zeaxanthin. The essential ingredients of the nutritional or dietary supplements are Vitamin C, no more than 300 IUs of Vitamin E, Vitamin A at least a portion of which is provided in the form of a proform Vitamin A carotenoid, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and / or zeaxanthin. The essential ingredients are provided in a form suitable of oral ingestion or other forms of administration in one or more doses per day.
Owner:PAUL JR EDWARD L

Laser system with short pulse characteristics and its methods of use

ActiveUS20060187978A1Reduce thermal effectsShort and controlled pulse width trainsLaser surgeryLaser detailsPulse characteristicsRetinal damage
A laser system that includes a diode pump source. A frequency doubled solid state visible laser is pumped by the diode pump source and produces a pulsed laser output with a train of pulses. Resources provide instructions for the creation of the pulsed output, with on and off times that provide for substantial confinement of thermal effects at a target site. This laser system results in tissue specific photoactivation (or TSP) without photocoagulation damage to any of the adjacent tissues and without causing full thickness retinal damage and the associated vision loss.
Owner:IRIDEX CORP

Method and apparatus for performing microcurrent stimulation (MSC) therapy

A method and apparatus for providing microcurrent stimulation (MSC) therapy. In accordance with the present invention, it has been determined that the application of microcurrent signals at particular frequencies to the eye for particular periods of time stabilizes and even improves conditions of macular degeneration and other ocular diseases. Experimental data from clinical trials shows that results of persons who underwent therapy are at least better than placebo, and that the therapy is safe and efficacious. In fact, experimental data from clinical trials showed that approximately 98% of the patients who underwent the MCS therapy of the invention experienced either stabilization or improvement of macular degeneration within one year of starting therapy. Of this percentage, approximately 65% of the patients subjected to the MCS therapy experienced improved vision, while approximately 32% experienced stabilization of macular degeneration (i.e., no further loss of vision).
Owner:ATLANTIC MEDICAL

System and method for sensory defect simulation

A visual defect simulation system receives a functional field map produced by an MRI system that relates locations in a patient's brain to locations in the patient's field of view. Planned medical operations are indicated at locations in the patient's brain and any resulting vision loss is simulated with a revised functional field map. A scene is displayed and an impairment overlay is produced from the revised functional field map that blocks the scene at locations corresponding to simulated vision loss. The overlay is translated over the scene in response to viewer eye movements detected by a vision-tracking system to present a real-time simulation of the resulting vision loss.
Owner:MCW RES FOUND INC

Nutritional or dietary supplement for the treatment of macular degeneration

A nutritional or dietary supplement composition that promotes retinal health through the prevention and / or treatment of visual acuity loss by reducing the risk of developing age-related macular degeneration in persons with early age-related macular degeneration. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, micronutrients and other antioxidants. The essential ingredients are provided in an oral dosage. The composition is taken in the form of one or two tablets or capsules daily.
Owner:KRAWITZ PAUL L

Metamorphopsia testing and related methods

A visual distortion test is disclosed using a sequence of binary interactions with a mobile device, in which segments of the grid having no distortions are eliminated, and the segments with distortions are divided into smaller segments for further analysis. The test can quantify the visual distortion using a decreased number of steps, compared to sequential analysis of all the segments of the grid. The binary interaction or input to the mobile device is also easier for patients than graphic interactions with a conventional Amsler Grid. Early detection of changes in the visual distortion can enable the healthcare provider to individualize treatment, helping to prevent vision loss while minimizing visits to the office, discomfort, and expense.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health

Compositions for maintaining, strengthening, improving, or promoting eye health comprise α-lipoic acid, ascorbic acid, and α-tocopherol, or pharmaceutical equivalents thereof. The compositions are useful to prevent, stabilize, reverse and / or treat visual acuity loss in subjects having, or being at risk of developing, an ocular disease. The compositions can further comprise one or more other antioxidants, beneficial minerals, and / or nutritional or dietary materials.
Owner:BAUSCH & LOMB INC

Vision test for determining retinal disease progression

The present invention provides a reading test to measure vision loss. In one embodiment, the vision loss is due to disease progression. The tests are useful in evaluating the effects of intervention in vision deterioration. The tests are non-invasive, simple, quick, sensitive, reproducible, and easy to administer. The tests measure the subject's reading speed and accuracy under defined conditions of illumination and contrast. The results of these tests may be used to determine if treatment of a disease should be initiated, terminated, altered, or remain unchanged.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Nutritional supplement for treatment of ocular diseases

A nutritional supplement composition that promotes visual health and reduces or reverses visual acuity loss by a reduced Vitamin E content from standard supplements with the addition of taurine, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and zeaxanthin. The essential ingredients of the nutritional or dietary supplements are Vitamin C, no more than 300 IUs of Vitamin E, Vitamin A at least a portion of which is provided in the form of a proform Vitamin A carotenoid, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and / or zeaxanthin. The essential ingredients are provided in a form suitable of oral ingestion or other forms of administration in one or more doses per day.
Owner:PAUL JR EDWARD L

Interactive Home Vision Monitoring Systems

Novel vision monitoring and diagnostic testing tools and help-seeking enablers that may be used individually or in combination as vision monitoring and diagnostic testing systems that improve patients' ability to recognize onset and progression of visual changes over time, so that the identification of acute or chronic visual conditions may be improved and accelerated, which drives earlier help-seeking behavior by the patient, which enables earlier clinical diagnosis by an eye care specialist and therefore earlier treatment and therefore reduced likelihood of severe vision loss.
Owner:ROSER MARK COSTIN

System, method, and non-transitory computer-readable storage media related to correction of vision defects using a visual display

A method of at-home monitoring of eye conditions using a head mounted display that is capable of establishing a visual model associated with a patient. The visual model may include data related to a quality of the patient's vision. The patient may use the system to establish a visual model periodically, such as daily, and the system may compare the visual model to previous visual models and send an alert to the patient's physician if changes meeting a given criteria are detected. This may allow the physician to immediately take steps to save the patient's eyesight where a delay in treatment may result in vision loss.
Owner:RAYTRX LLC

Nutritional supplement to treat macular degeneration

ActiveUS20050163864A1Decrease visual acuity lossEffective preventionPowder deliveryBiocideVitamin CBeta-Carotene
A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and / or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, vitamin E, beta-carotene, zinc and copper. The essential ingredients are preferably provided in a tablet form suitable for oral ingestion. Preferably the composition is taken in the form of one or two tablets taken twice daily.
Owner:BARCLAYS BANK PLC AS SUCCESSOR AGENT

Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions

The invention relates to a cellprotective, neuroprotective and retinoprotective composition. In an embodiment of the invention, said composition comprises (i) Ramipril or Ramiprilate and (ii) folic acid. The composition of the invention can be used, in particular, for the prevention of loss of vision, or even for improving visual acuity and visual field in normal subjects, as well as for treating ophthalmologic pathologies, in particular: glaucoma, diabetic retinopathy, age related macular degeneration, hereditary dystrophy of the retina, uveitis, ammetropia (myopia, presbyopia). This combination of active principles could also be used in general conditions for treating general pathologies (cancer...).
Owner:拉乌夫·雷基克

Composition for optic nerve protection

A composition for optic nerve cell protection, for preventing or treating glaucoma, for suppressing retinal ganglion cell death, or for delaying a progression of visual acuity loss of human contains at least one selected from the group consisting of products obtained by steaming and drying wheat, defatted wheat germ, defatted rice germ, defatted soybean, fermented grape, hesperidin, lactic acid bacterium Lactobacillus salivarius, wild grape, Tamarind, Haskap, pomegranate seeds, licorice powder, and cinnamon powder.
Owner:TOHOKU TECHNO ARCH CO LTD +1

Systems and methods for promoting medication adherence

ActiveCN109589269AReduce sizePharmaceutical containersMedical packagingPromoting medication adherenceMedical treatment
A system for promoting medication adherence is provided. The system may receive medical information and medication access information via a medication adherence device, the medication adherence devicehaving a housing configured to be removably coupled to a medicine container top and an access switch, the access switch generating medication access information when the housing is uncoupled from themedicine container top. The information may be used to form one or more blind spots which may be representative of symptoms of glaucoma and which may be produced on the display screen of a patient'sclient device. The system may use Gamblification and / or Gamification in which a blind spot obscures portions of a game of chance program and / or novelty game type program, respectively, from being observed on the display screen of the client device. As medical information and medication compliance information is received, the number, size, opacity, and / or shape of the blind spots produced on the display screen of a patient's client device may change to provide actual perception of visual loss which spurs patients to compliance.
Owner:AGAPE ASSETS LLC

Systems and methods for improving medication adherence

The present invention provides a system for improving medication compliance. The system may receive medical information and medication access information through a medication adherence device having a housing and an access switch, the housing configured to be detachably attached to the top of the medication container, when the housing is attached to the medication container When the top is detached, the access switch generates medication access information. This information can be used to form one or more blind spots, which can represent symptoms of glaucoma and can be generated on a display screen of the patient's client device. The system may use gaming and / or gamification in which blind spots block portions of the game of chance and / or game-type programming, respectively, from view on the display screen of the client device. The number, size, opacity, and / or shape of the blind spots created on the display screen of the patient's client device may change to provide an actual perceived loss of vision that stimulates the loss of vision when medical information and medication compliance information is received The patient complies.
Owner:AGAPE ASSETS LLC

Uses of dan family bmp antagonists for inhibiting ocular neovascularization and treating ocular conditions

PendingUS20220265772A1Prevention and treatment of visual impairmentInhibit neovascularizationSenses disorderPeptide/protein ingredientsOcular neovascularizationPharmacology
Described herein are methods and pharmaceutical compositions for the prevention and / or treatment of visual impairment and vision loss, and more particularly to the use of DAN family BMP antagonist(s) for the prevention of ocular neovascularization and, as a trophic factor for photoreceptors in eye diseases. Also described is a method for long-term inhibition of neovascularization in an ocular condition, a method of replacement therapy for vascular endothelial growth factor (VEGF) inhibitor treatment and a method for inhibiting and / or preventing ocular neovascularization and / or ocular angiogenesis in a mammalian subject, the methods comprising administering to a mammalian subject in need an effective amount a DAN family BMP antagonist such as DAND5.
Owner:9636137 CANADA INC

Vision test for determining retinal disease progression

The present invention provides a reading test to measure vision loss. In one embodiment, the vision loss is due to disease progression. The tests are useful in evaluating the effects of intervention in vision deterioration. The tests are non-invasive, simple, quick, sensitive, reproducible, and easy to administer. The tests measure the subject's reading speed and accuracy under defined conditions of illumination and contrast. The results of these tests may be used to determine if treatment of a disease should be initiated, terminated, altered, or remain unchanged.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Nutritional supplements for eye health and related methods

ActiveUS20140093489A1Strengthens and promotes general eye health and healthStrengthens and promotes health and retinal healthBiocideSenses disorderOlder peopleTherapy vision
A nutritional or dietary supplement composition that strengthens and promotes a general eye health benefit for aging adults, including retinal health through the prevention, stabilization, reversal and / or treatment of visual acuity loss by reducing the risk of developing late stage or advanced age-related macular degeneration in persons with early age-related macular degeneration. The nutritional or dietary supplement composition may likewise reduce the risk of vision loss associated with the development of cataracts.
Owner:OHIO STATE INNOVATION FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products